Syndax [SNDX] vs Dyne Therapeutics [DYN] Detailed Stock Comparison
Syndax
NASDAQ
Loading...
Dyne Therapeutics
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Syndax wins in 8 metrics, Dyne Therapeutics wins in 7 metrics, with 0 ties. Syndax appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Syndax | Dyne Therapeutics | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -4.18 | -3.90 | Syndax |
| Price-to-Book Ratio | 8.50 | 2.63 | Dyne Therapeutics |
| Debt-to-Equity Ratio | 219.49 | 21.19 | Dyne Therapeutics |
| PEG Ratio | -1.11 | -0.10 | Syndax |
| EV/EBITDA | -3.59 | -2.98 | Syndax |
| Profit Margin (TTM) | 96.51% | 0.00% | Syndax |
| Operating Margin (TTM) | -182.71% | 0.00% | Dyne Therapeutics |
| Return on Equity | -113.22% | -61.32% | Dyne Therapeutics |
| Return on Assets (TTM) | -39.50% | -35.45% | Dyne Therapeutics |
| Free Cash Flow (TTM) | $-274.90M | $-294.75M | Syndax |
| 1-Year Return | -18.67% | -61.39% | Syndax |
| Price-to-Sales Ratio (TTM) | 17.19 | N/A | N/A |
| Enterprise Value | $1.22B | $1.31B | Dyne Therapeutics |
| EV/Revenue Ratio | 15.61 | N/A | N/A |
| Gross Profit Margin (TTM) | 96.63% | N/A | N/A |
| Revenue per Share (TTM) | $1 | $0 | Syndax |
| Earnings per Share (Diluted) | $-3.89 | $-3.88 | Dyne Therapeutics |
| Beta (Stock Volatility) | 0.72 | 1.10 | Syndax |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Syndax vs Dyne Therapeutics Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Syndax | -5.01% | -8.74% | 19.89% | 45.74% | 18.52% | 10.44% |
| Dyne Therapeutics | -0.19% | -7.52% | 13.17% | -9.06% | 6.39% | -48.35% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Syndax | -18.67% | -32.80% | -8.58% | 31.22% | 31.22% | 31.22% |
| Dyne Therapeutics | -61.39% | -3.66% | -42.32% | -42.32% | -42.32% | -42.32% |
News Based Sentiment: Syndax vs Dyne Therapeutics
Syndax
News based Sentiment: POSITIVE
Syndax reported exceptional Q2 results and continued to showcase strong sales figures throughout September, attracting positive analyst attention. The upcoming FDA decision on October 25, 2025, for Revumenib represents a significant catalyst, but the company still faces challenges in achieving profitability, creating a balanced investment narrative.
Dyne Therapeutics
News based Sentiment: POSITIVE
September was a significant month for Dyne Therapeutics, marked by positive clinical data for their DM1 program, active investor engagement at key conferences, and a clear timeline for upcoming data readouts and BLA submissions. These developments strengthen the investment case and suggest the company is progressing towards potential commercialization, though risks related to trial outcomes and regulatory approval remain.
Performance & Financial Health Analysis: Syndax vs Dyne Therapeutics
| Metric | SNDX | DYN |
|---|---|---|
| Market Information | ||
| Market Cap | $1.34B | $1.87B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 1,760,260 | 2,080,960 |
| 90 Day Avg. Volume | 2,610,963 | 2,782,247 |
| Last Close | $15.55 | $13.15 |
| 52 Week Range | $8.58 - $22.50 | $6.36 - $37.08 |
| % from 52W High | -30.89% | -64.54% |
| All-Time High | $29.86 (Jan 30, 2023) | $47.45 (Aug 19, 2024) |
| % from All-Time High | -47.92% | -72.29% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 9.85% | N/A |
| Quarterly Earnings Growth | 9.85% | N/A |
| Financial Health | ||
| Profit Margin (TTM) | 0.97% | 0.00% |
| Operating Margin (TTM) | -1.83% | 0.00% |
| Return on Equity (TTM) | -1.13% | -0.61% |
| Debt to Equity (MRQ) | 219.49 | 21.19 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $1.83 | $5.00 |
| Cash per Share (MRQ) | $5.44 | $4.81 |
| Operating Cash Flow (TTM) | $-302,667,008 | $-359,560,000 |
| Levered Free Cash Flow (TTM) | $-173,729,744 | $-222,398,000 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Syndax vs Dyne Therapeutics
| Metric | SNDX | DYN |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -4.18 | -3.90 |
| Forward P/E | -4.39 | -4.16 |
| PEG Ratio | -1.11 | -0.10 |
| Price to Sales (TTM) | 17.19 | N/A |
| Price to Book (MRQ) | 8.50 | 2.63 |
| Market Capitalization | ||
| Market Capitalization | $1.34B | $1.87B |
| Enterprise Value | $1.22B | $1.31B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 15.61 | N/A |
| Enterprise to EBITDA | -3.59 | -2.98 |
| Risk & Other Metrics | ||
| Beta | 0.72 | 1.10 |
| Book Value per Share (MRQ) | $1.83 | $5.00 |
Financial Statements Comparison: Syndax vs Dyne Therapeutics
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | SNDX | DYN |
|---|---|---|
| Revenue/Sales | $37.96M | $0 |
| Cost of Goods Sold | $1.28M | N/A |
| Gross Profit | $36.68M | N/A |
| Research & Development | $62.23M | $99.24M |
| Operating Income (EBIT) | $-69.35M | $-115.79M |
| EBITDA | $-63.99M | $-110.26M |
| Pre-Tax Income | $-71.85M | $-110.86M |
| Income Tax | N/A | N/A |
| Net Income (Profit) | $-71.85M | $-110.86M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | SNDX | DYN |
|---|---|---|
| Cash & Equivalents | $153.99M | $472.26M |
| Total Current Assets | $548.75M | $689.50M |
| Total Current Liabilities | $94.55M | $33.88M |
| Long-Term Debt | $1.45M | $18.22M |
| Total Shareholders Equity | $215.06M | $668.97M |
| Retained Earnings | $-1.31B | $-1.07B |
| Property, Plant & Equipment | $1.80M | $34.19M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | SNDX | DYN |
|---|---|---|
| Operating Cash Flow | $-95.02M | $-110.37M |
| Capital Expenditures | N/A | $-981,000 |
| Free Cash Flow | $-95.16M | $-106.87M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | SNDX | DYN |
|---|---|---|
| Shares Short | 20.92M | 16.04M |
| Short Ratio | 7.20 | 5.24 |
| Short % of Float | 0.27% | 0.13% |
| Average Daily Volume (10 Day) | 1,760,260 | 2,080,960 |
| Average Daily Volume (90 Day) | 2,610,963 | 2,782,247 |
| Shares Outstanding | 85.69M | 102.32M |
| Float Shares | 72.69M | 122.63M |
| % Held by Insiders | 0.01% | 0.00% |
| % Held by Institutions | 1.21% | 0.95% |
Dividend Analysis & Yield Comparison: Syndax vs Dyne Therapeutics
| Metric | SNDX | DYN |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |